Nantahala Capital Management LLC Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Nantahala Capital Management LLC acquired a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,243,513 shares of the company's stock, valued at approximately $1,965,000. Nantahala Capital Management LLC owned about 3.56% of RAPT Therapeutics as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Picton Mahoney Asset Management lifted its holdings in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after purchasing an additional 14,697 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after buying an additional 25,130 shares in the last quarter. Sei Investments Co. bought a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $64,000. Barclays PLC boosted its position in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after acquiring an additional 29,195 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after acquiring an additional 42,636 shares in the last quarter. Institutional investors own 99.09% of the company's stock.

RAPT Therapeutics Price Performance

RAPT traded up $0.05 on Friday, hitting $0.97. 904,905 shares of the stock were exchanged, compared to its average volume of 1,279,842. The firm has a market capitalization of $127.62 million, a price-to-earnings ratio of -0.35 and a beta of -0.29. RAPT Therapeutics, Inc. has a 12 month low of $0.75 and a 12 month high of $8.58. The business has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). Equities research analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $4.00.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.